Investing in Cardiometabolic Disease: Why the Largest Disease Category in Medicine Is Still Early

What is cardiometabolic disease, and why treat it as one category?

Cardiometabolic disease is the interconnected cluster of conditions that share a common metabolic root: atherosclerotic cardiovascular disease and heart failure, type 2 diabetes, obesity, dyslipidemia, hypertension, chronic kidney disease of metabolic origin, and metabolic liver disease, now commonly termed metabolic dysfunction-associated steatohepatitis, or MASH, under nomenclature that replaced the older NASH terminology. These are not separate silos. They travel together because they share upstream biology: insulin resistance, ectopic and visceral fat, chronic low-grade inflammation, and lipotoxicity that stresses the vasculature, the myocardium, the kidney, and the liver in parallel.

Treating them as one category is not a marketing convenience, it is a scientific and clinical reality. A patient with obesity carries elevated risk for type 2 diabetes, which accelerates atherosclerosis, which contributes to heart failure and kidney decline, while the same metabolic milieu deposits fat in the liver and can progress toward fibrosis. A therapy that moves the upstream node can, in principle, bend multiple downstream curves at once. That is broadly what the incretin class demonstrated, and it is why cardiometabolic disease deserves to be evaluated by investors as a single, deeply linked opportunity space rather than a set of unrelated indications.

How large is the burden, and why does scale matter to an investor?

Cardiovascular disease has for many years been described by public-health data as the leading cause of death globally, and obesity and type 2 diabetes have risen steadily across most regions measured. Metabolic liver disease is now understood to be among the most common chronic liver conditions in the general population. We deliberately avoid citing precise figures that shift year to year, but the direction is long-standing and unambiguous: these conditions affect a very large share of adults and account for a substantial fraction of total healthcare spending.

For an early-stage investor, scale matters in a specific way. It shapes the addressable market and the tolerance of payers and health systems for new mechanisms. When the prevalent population is very large, even a therapy or diagnostic that serves a well-defined subpopulation can support a durable company. Scale also raises the clinical and regulatory bar, because the standard of care is entrenched and inexpensive generics exist for many upstream risk factors such as hypertension and dyslipidemia. A strong cardiometabolic company is one whose science is large enough to matter and specific enough to win.

What did the GLP-1 and incretin era actually prove?

The incretin story reset expectations for the entire field. GLP-1 receptor agonists, developed first for glycemic control in type 2 diabetes, were found to produce clinically meaningful weight loss, and later dual GIP and GLP-1 receptor agonism pushed efficacy further. Agents in this broad class have generated cardiovascular and other outcome data that moved them from glucose-lowering drugs toward agents with broader organ-protective evidence, and related programs have reported benefit signals extending into areas such as heart failure, kidney disease, and metabolic liver disease. The specifics vary by molecule and by trial, and each claim rests on its own dataset.

The deeper lesson for investors is threefold. First, metabolic biology is druggable at the level of appetite, energy balance, and organ crosstalk, not merely at the level of a single downstream lab value. Second, patients and physicians will adopt chronic therapies at scale when the effect size is real and the safety profile is manageable. Third, and most important for early-stage strategy, the incretin wave did not close the field, it opened it. It created a reference efficacy against which every new mechanism is now measured, and it exposed the problems that first-generation agonists do not solve.

What problems remain unsolved after the first incretin wave?

The open questions are where the next generation of companies will be built. Weight regain after discontinuation is well documented, which raises the question of durability and whether metabolic set points can be reset rather than merely suppressed. A meaningful share of the weight lost on current agents is lean mass, not only fat, which has driven interest in muscle-preserving mechanisms such as activin and myostatin pathway modulation. Gastrointestinal tolerability limits titration for many patients. Access, cost, and the burden of injectable chronic therapy remain real constraints, motivating oral small-molecule and peptide approaches.

Beyond weight, the frontier extends into mechanism diversity and organ specificity. Non-incretin appetite and energy-expenditure pathways, liver-directed therapies for MASH fibrosis where the first approvals are recent and the field is still defining responders, precision approaches that stratify patients by genotype or metabolic phenotype, and combination regimens that pair an incretin backbone with a complementary agent all represent white space. For a founder emerging from an academic lab, the question is not how to build a slightly better agonist, it is which unsolved node of this biology their discovery uniquely addresses.

• Durability and weight regain after therapy is stopped
• Preservation of lean muscle mass during weight loss
• Oral and non-injectable delivery to widen access
• Non-incretin and combination mechanisms for non-responders
• MASH fibrosis regression and reliable responder identification
• Precision stratification by metabolic phenotype or genetics

What is a cardiovascular outcome trial, and why does it govern the whole field?

Regulators and payers in cardiometabolic disease increasingly want to see hard outcomes, not only changes in a biomarker. A cardiovascular outcome trial, often abbreviated CVOT, is a large, long, randomized study powered to show that a therapy reduces major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and stroke, sometimes with extended endpoints including heart failure hospitalization and kidney progression. These trials commonly enroll thousands of patients and run for multiple years, because events accrue slowly even in the populations most likely to benefit.

This reality shapes company building from the first check onward. A CVOT is expensive and time-consuming, which means a pre-seed company will not run one itself, but its entire strategy must anticipate one. The mechanism must be plausibly linked to outcomes, the early biomarker package must build a credible bridge to a future CVOT, and the eventual value inflection often depends on a pharmaceutical partner or acquirer who can fund that trial. For MASH and metabolic liver disease, the analogous requirement is histologic or, increasingly, non-invasive evidence of fibrosis improvement over long horizons. Founders who understand this from the start design their preclinical and early clinical work to de-risk the endpoints that ultimately matter, rather than optimizing for the endpoints that are merely easy to hit.

How do therapeutics, devices, and diagnostics fit together?

Cardiometabolic disease is one of the rare areas where all three modalities interact rather than compete. Therapeutics carry the largest headline value, but devices and diagnostics increasingly determine who gets treated, how well, and how the effect is measured. Continuous glucose monitoring reshaped diabetes management and is now extending into metabolic health more broadly. Digital and closed-loop systems, implantable and neuromodulation approaches to appetite and metabolism, and cardiac and structural-heart devices all sit within this territory.

Diagnostics may be the most underappreciated leverage point for an early investor. As therapy proliferates, the binding constraint shifts from whether a drug exists to which patient should receive which mechanism, and how progression is tracked without invasive procedures. Non-invasive liver fibrosis assessment, polygenic and proteomic risk stratification for cardiovascular events, and biomarkers that identify incretin non-responders or predict weight regain can all support durable, defensible businesses. A diagnostic that becomes the trial-enrollment or treatment-selection standard can be as strategically valuable as a therapeutic, and it often carries a shorter and less capital-intensive path to a first clinical inflection.

What does a great early cardiometabolic spinout look like?

The strongest university spinouts we see share a recognizable structure. They originate from a specific, non-obvious biological insight, often a target, pathway, or measurement that the founding lab discovered and can defend with real intellectual property. They address one of the unsolved nodes rather than reprising a validated mechanism. They hold a clear and honest view of the endpoint they will eventually have to clear, whether that is a cardiovascular outcome, a histologic liver endpoint, or a clinically validated diagnostic performance threshold. And they are led by, or tightly partnered with, someone who has operated in drug or device development before, because cardiometabolic timelines punish teams that learn the regulatory reality late.

A great spinout also demonstrates modality honesty. The best founders know whether they are building a therapeutic that will need a partner for a CVOT, a device with a defined regulatory pathway, or a diagnostic that must embed into clinical workflow and reimbursement. They can articulate why their mechanism should be complementary to an incretin backbone rather than displaced by it, and they can name the specific patient they help that current therapy does not. Precision and self-awareness about the path, not breadth of ambition, is the signal we listen for.

• A defensible, specific scientific insight with clean IP out of the founding lab
• A mechanism aimed at an unsolved node, complementary to the incretin standard
• A credible bridge from early biomarkers to the outcome that ultimately matters
• Operator-led leadership that has navigated development timelines before
• Modality clarity on the therapeutic, device, or diagnostic path and its capital needs

How does Sonnerie evaluate cardiometabolic opportunities?

Sonnerie invests at pre-seed and seed, frequently as the first institutional check into a university spinout. In cardiometabolic disease that means we are underwriting science years before a pivotal trial, so our diligence concentrates on the questions that determine whether a durable company can exist at all. We ask whether the biology is differentiated against the incretin standard, whether the intellectual property genuinely protects the insight, and whether the team understands the outcome trial or diagnostic validation that stands between them and scale.

We look for the signal in the noise, the specific mechanism or measurement that will still matter after the current wave of agonists has saturated the obvious indications. We weigh the interplay of therapeutics, devices, and diagnostics rather than treating them as separate lanes, because in this field the diagnostic often decides the therapeutic and the device often extends it. And we back operators, founders and scientific leaders who can carry a program from an academic result through the unglamorous years of endpoint de-risking toward a partner or an inflection. Large prevalence indicates the market is real. Scientific specificity and operator discipline are what turn that market into a company, and that is what we look for from signal to scale. None of this is investment advice, it is how we think about the science and the market.